Format

Send to

Choose Destination
Expert Rev Gastroenterol Hepatol. 2016 Jun;10(6):723-33. doi: 10.1586/17474124.2016.1142872. Epub 2016 Mar 2.

Management of NSAID-associated peptic ulcer disease.

Author information

1
a Unidad de Gastroenterología, Servicio de Digestivo , Corporació Sanitària Parc Taulí , Sabadell , Spain.
2
b Departament de Medicina , Universitat Autònoma de Barcelona , Sabadell , Spain.
3
c CIBERehd , Instituto Carlos III , Madrid , Spain.

Abstract

Non-steroidal anti-inflammatory drug (NSAID) use increases the risk of gastrointestinal complications such as ulcers or bleeding. The presence of factors like advanced age, history of peptic ulcer, Helicobacter pylori infection and the use of anticoagulants or antiplatelet agents increase this risk further. COX-2 inhibitors and antisecretory drugs, particularly proton pump inhibitors, help to minimize the risk of gastrointestinal complications in high-risk patients. This review presents a practical approach to the prevention and treatment of NSAID-associated peptic ulcer disease and examines the new advances in the rational use of NSAIDs.

KEYWORDS:

COX-2 selective inhibitors; Cardiovascular risk; Gastrointestinal bleeding; Gastrointestinal risk; Gastroprotection; Low dose aspirin; NSAID gastropathy; Non-steroidal anti-inflammatory drugs; Upper gastrointestinal complications

PMID:
26775657
DOI:
10.1586/17474124.2016.1142872
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center